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Interleukin-17Our understanding of the pathophysiology of multiple sclerosis (MS) has evolved signiﬁcantly over the past
two decades as the ﬁelds of immunology and neurobiology provide new avenues of exploration into the
cause and mechanism of the disease. It has been known for decades that T cells have different cytokine
phenotypes, yet the cytokine phenotype of pathogenic T cells in MS is still an area of debate. In EAE, it
appears that IFNγ and IL-17, produced by Th1 and Th17 cells respectively, are not the critical factor that
determines T cell encephalitogenicity. However, there are molecules such as IL-23, T-bet and STAT4, that
appear to be critical, yet it is unclear whether all these molecules contribute to a common, yet undeﬁned
pathway, or act in a synergistic manner which culminates in encephalitogenicity has still to be determined.
Therefore, the focus of research on effector T cells in MS should focus on pathways upstream of the cytokines
that deﬁne Th1 and Th17 cells, since downstream products, such as IFNγ and IL-17, probably are not critical
determinants of whether an effector T cells is capable of trafﬁcking to the CNS and inducing inﬂammatory
demyelination.+1 614 292 7544.
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Our understanding of the pathophysiology of multiple sclerosis
(MS) has evolved signiﬁcantly over the past two decades as the ﬁelds
of immunology and neurobiology provide new avenues of exploration
into the cause and mechanism of the disease.
Experimental autoimmune encephalomyelitis (EAE) has been
used as a model for multiple sclerosis (MS) for more than 40 years
and has been amajor factor in determining the path ofMS research. As
the ﬁeld of immunology advances, many of the fundamental
observations in EAE are questioned and revisited to further our
understanding of immune-mediated neurodegeneration with the
ultimate goal of deﬁning the pathophysiology of MS and develop-
ment of a cure. Although MS is speculated to be a T cell-mediated
autoimmune disease directed against myelin proteins, the cause of the
disease is unknown. It has been known for decades that T cells have
different cytokine phenotypes, yet the cytokine phenotype of
pathogenic T cells in MS is still an area of debate. Understanding the
phenotype of the T cells that mediate MS and other autoimmune
diseases may be essential to determining the cause of disease and the
development of therapies.2. CD4 T cell cytokine phenotype in EAE
The EAE model evolved from the observation that a small number
of individuals receiving the rabies virus vaccine, a live attenuated
strain grown in rabbit CNS, developed encephalomyelitis. The
realization that the encephalomyelitis was not caused by the rabies
virus, but a hypersensitivity to the CNS debris contaminating the
vaccine, initiated the development of EAE as a model for MS. Although
EAE was initially induced by immunization with myelin proteins
emulsiﬁed in Complete Freund's Adjuvant, it can also be induced by
adoptive transfer of myelin-speciﬁc CD4+ TH1 cells into naïve
recipient mice [1–7]. Since myelin-speciﬁc CD4+ TH1 cells were
sufﬁcient to induce EAE, MS research focused on these IFNγ-
producing T cells in MS patients. Several studies that speciﬁcally
suppressed IFNγ in the myelin-speciﬁc T cells prior to transfer into
recipient mice demonstrated that altering the signaling pathway
which results in IFNγ production in CD4+ T cells decreases the
encephalitogenic capacity of these cells [6,8,9]. In addition, STAT4 and
T-bet, which are transcription factors in the TH1 differentiation
pathway, have been shown to be essential for EAE induction [6,10–
12]. The critical experiment to determine if IFNγ was in fact a viable
target for autoimmune encephalomyelitis was the induction of EAE in
IFNγ and IFNγ receptor deﬁcient mice [13,14]. Not only were IFNγ-
deﬁcient mice susceptible to EAE, the disease appeared to be more
severe. This observation was conﬁrmed with systemic administration
of antibodies to neutralize IFNγ [15,16]. The number ofmyelin-speciﬁc
CD4+ T cells was expanded in IFNγ-deﬁcient mice, which may have
occurred due to loss of regulatory cells that were dependent on IFNγ
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generates TH1 cells may be important in encephalitogenicity, but the
downstream production of IFNγ by myelin-speciﬁc T cells is not
critical.
The realization that CD4+ TH1 cells were sufﬁcient to cause EAE,
yet IFNγ was not necessary, caused many investigators to look at
other cytokines that may inﬂuence pathogenic capacity of T cells or
focus on other characteristics of T cells such as signaling and
transcription proteins. Since IL-12 was necessary for signaling events
that promote the differentiation of TH1 cells, mice deﬁcient in the p40
and p35 proteins which comprise IL-12 were deleted in mice and EAE
was evaluated. Although IL-12p40 deﬁcient mice failed to develop
EAE, the IL-12p35-deﬁcient mice did develop EAE [18,19]. Since IL-
12p40 was also a component of IL-23, the IL-23 speciﬁc protein p19
was deleted in mice and these mice were also resistant to EAE [20]. As
a result, IL-23 was deemed an essential cytokine in EAE development,
whereas IL-12 was not. In 2005, it was found that IL-23 could promote
the expansion of myelin-speciﬁc IL-17+ T cells derived from MOG
immunized mice and these IL-23-driven IL-17+ T cells were capable
of transferring EAE [21]. This led to speculation that myelin-speciﬁc
TH17 cells were the primary encephalitogenic T cell population in EAE,
and perhaps MS. Development of IL-17-deﬁcient mice illustrated that
although EAE was less severe in the absence of IL-17, IL-17 was also
not necessary for the development of EAE [22,23]. Although IL-23 can
enhance IL-17 production, the difference in susceptibility to EAE
suggests that the essential role of IL-23 in EAE induction is not linked
to its ability to promote IL-17 expression. The data from both the IFNγ
and IL-17 deﬁcient mice suggested that cytokine production by
myelin-speciﬁc T cells, although an easy potential therapeutic target,
was not the determining factor for CD4 T cell encephalitogenicity.
Several studies found that IL-6 and TGFβ were sufﬁcient to
differentiate CD4 T cells into Th17 cells in vitro [24–26]. However,
Th17 cells generated by differentiation with IL-6 and TGFβ in vitro are
not encephalitogenic when transferred into naïve recipient mice,
suggesting that this is not the mechanism that occurs in vivo to
generate pathogenic Th17 cells in EAE [27]. Recently, it has been
demonstrated that TGFβ is dispensable during Th17 differentiation,
and that IL-6 in the absence of cytokines that promote Th1 or Th2
differentiation will generate Th17 cells that are encephalitogenic
[27,28]. Thus, it appears that Th1, Th2 and Th17 cells differentiate in
distinct cytokine microenvironments which may be inﬂuenced by the
host interactions with environmental factors such as pathogens.
3. Transcriptional regulation of CD4 T cell differentiation
Counter-intuitive data generated from mice deﬁcient in transcrip-
tion factors that play critical roles in T cell differentiation have also
complicated attempts to deﬁne the pathogenic T cell population in
EAE. Naïve CD4 T cells require both T cell receptor engagement with
peptides presented byMHC class II molecules, as well as costimulation
mediated by CD28 and B7 molecules. In addition, cytokines in the
micro-environment inﬂuence the phenotype of CD4 T cells. TH1 cells
develop when the environment is rich in IFNγ and IL-12 (Fig. 1A).
IFNγ binds to the constitutively expressed IFNγ receptor (IFNγR) on
the surface of naïve CD4 T cells which results in phosphorylation of
STAT1 (pSTAT1) and its translocation (Fig. 1C). pSTAT1 contributes to
the transcription of T-bet which promotes the transcription of STAT1,
and thus a positive feedback loop exists between these two
transcription factors that initially drive a CD4 T cell towards a TH1
phenotype. pSTAT1 and possibly T-bet transcriptionally activate the
IL-12Rβ2, which is the inducible chain of the IL-12 receptor and forms
a heterodimer with the constitutively expressed IL-12Rβ1 chain,
forming a complete IL-12R on the cell surface. IL-12 in the micro-
environment binds to the IL-12R, resulting in STAT4 phosphorylation,
translocation and binding to the IFNγ promoter. It has been
demonstrated that pSTAT1, pSTAT4 and T-bet all bind to the IFNγpromoter, as well as other transcription factors, and initiate IFNγ
production and contribute to the full differentiation of a TH1 cell
(Fig. 1C). Mice deﬁcient in STAT4 and T-bet are resistant to EAE
induction, suggesting that the Th1 differentiation pathway is
necessary for the generation of encephalitogenic CD4 T cells
[6,10,11]. However, STAT1 mice are susceptible to EAE indicating
the IFNγ receptor signaling is not essential for disease induction [11].
RORγt has been identiﬁed as the essential transcriptional regulator
of Th17 cells. Mice deﬁcient in RORγt have attenuated EAE [29];
however, these mice do not form lymph nodes [30]. Thus, the
resistance to EAE may be due to the inability of CD4 T cells to be
activated and differentiate in the periphery, andmay be unrelated to a
failure to generate Th17 cells. In fact, T-bet deﬁcient mice generate a
high frequency of myelin-speciﬁc Th17 cells upon EAE induction [27],
yet fail to develop disease [11]; further indicating that myelin-speciﬁc
Th17 cells are not sufﬁcient to cause EAE. Ex vivo analysis of myelin-
speciﬁc T cells from mice immunized with MOG35-55 peptide
indicates that T-bet is found in both Th1 and Th17 cells, suggesting
that T-bet plays a role in T cell encephalitogenicity that is unrelated to
the cytokine proﬁle of the autoreactive T cells [27]. Generation of Th17
cells with IL-6 in the absence of exogenous TGFβ generates Th17 cells
that express T-bet and can induce EAE when transferred into mice
[27]. Although it is unclear what critical gene T-bet is regulating in
encephalitogenic T cells, the IL-23 receptor and osteopontin genes
have been shown to be regulated by T-bet [7,31]. Although
osteopontin deﬁcient mice have reduced EAE severity [32,33], IL-23
deﬁcient mice are not susceptible to EAE [20], suggesting the IL-23
receptor gene may be the essential gene regulated by T-bet.
4. Role of cytokine phenotype on T cell trafﬁcking and
cell recruitment
One potential role of the cytokine phenotype is to mediate
trafﬁcking of myelin-speciﬁc T cells to distinct sites within the CNS
which yield different functional deﬁcits. Several studies have noted
unique behavioral changes associated with myelin-speciﬁc Th17 cells
in EAE. In contrast to classical EAE induced by Th1 cells in which mice
develop an ascending paralysis, EAE induced by Th17 cells is often
characterized by spinning (dysequilibrium), ataxia, spasticity and
proprioceptive defects [34]. Analysis of the distribution of Th1 and
Th17 cells within the CNS revealed that inﬁltration of the brain
parenchyma occurs when the number of Th17 cells exceeds the
number of Th1 cells [34] (Fig. 1B). However, a wide range of Th1:Th17
ratios permitted spinal cord parenchymal inﬂammation. This suggests
that Th17 cells may preferentially migrate to the brain, generating
plaques at distinct sites with different functional losses. This was
conﬁrmed by administering an IL-17 neutralizing antibody to EAE-
affected mice which resulted in a decrease in atypical EAE and an
increase in classical EAE [34]. It should be noted that the absolute
number of Th1 cells inﬁltrating the CNS in EAE induced by
immunization far exceeds the number of Th17 cells, and lesions in
the spinal cord are more prevalent early in the disease.
Adhesion molecules clearly contribute to EAE and MS has
evidenced by the success of natalizumab, the anti-VLA4 antibody
used to treatMS. In 1992, VLA4was identiﬁed as the primary adhesion
molecule mediating the attachment of lymphocytes to the CNS
vascular endothelium [35]. It was subsequently observed that myelin-
speciﬁc Th1 cells that expressed VLA4 were highly encephalitogenic,
while myelin-speciﬁc Th1 cells that had minimal VLA4 expression
were not encephalitogenic [36]. These two studies prompted the
development of a humanized VLA4 antibody for the treatment of MS.
Although natalizumab therapy has been complicated by rare cases of
Progressive Multifocal Leukoencephalopathy [37], it has proven very
effective in controlling CNS inﬂammation in MS patients [38]. Ex vivo
analysis of VLA4 expression on CSF lymphocytes from MS patients
illustrates that both Th1 and Th17 cells express high levels of VLA4
Fig. 1. Th1 and Th17 cell differentiation and trafﬁcking to the CNS. (A) Naïve CD4 T cells can differentiate into Th1 or Th17 cells. During Th17 cell differentiation, TGFβ can enhance IL-17
production, but this diminishes the capacity of these cells to induce EAE. (B) The distribution of Th1 and Th17 cells within the CNS various in EAE. Th1 cells home preferentially to the
spinal cord, while Th17 cells appear to preferentially trafﬁc to the brain. The number of Th1 cells in the CNS signiﬁcantly outnumbers Th17 cells in myelin-immunized mice.
(C) Transcriptional regulation of Th1 and Th17 differentiation lends insight into signaling pathways that may be important in the development of encephalitogenic T cells. T-bet is found
encephalitogenic Th1 and Th17 cells. The presence of TGFβ during Th17 cell differentiation contributes to the inhibition of T-bet, resulting in non-encephalitogenic Th17 cells if primed
with IL-6+TGFβ.
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that VLA4 expression plays a critical role in effector T cell entry into
the CNS, regardless of cytokine phenotype.
Lesions in the spinal cords of mice immunized to induce EAE have
high numbers of macrophages and activated microglia, a classic
indicator of a Th1-driven inﬂammatory response. Consistent with this
observation is the upregulation of ELR-CXC chemokines, CXCL9,
CXCL10 and CXCL11, which are upregulated in the CNS of EAE-
affected mice induced by transfer of Th1 cells [40]. In contrast, lesions
induced by transfer of IL-23 driven Th17 cells are characterized by
massive neutrophil recruitment and upregulation of the neutrophil-
attracting ELR+CXC chemokines, CXCL1 and CXCL2 [40]. The critical
role of IL-23 in the development of CNS inﬂammation was originally
thought to be due to its role in enhancing IL-17 production, but more
recently it has been found that IL-23 plays a critical role in homing to
the CNS and survival of myelin-speciﬁc T cells in the CNS
microenvironment [41]. This reconciles the data that IL-23 deﬁciency
results in no disease, while IL-17 deﬁciency results in less severe EAE.
Since loss of IL-23 prevents CNS inﬂammation there is no disease
onset, while loss of IL-17 reduces neutrophil recruitment and
secondary damage mediated by matrix metalloproteases. There has
been speculation that IL-23 may inﬂuence T cell trafﬁcking by
modulating a chemokine receptor, such as CCR6 which has beenshown to be highly expressed on human Th17 [39,42]. However, there
is contradictory data in CCR6 mice with regard to their EAE
susceptibility [43–46], making it difﬁcult to determine whether
CCR6 is in fact a relevant player in the recruitment of Th17 cells to
the brain. Interestingly, IL-23 driven Th17 cells also cause severe
inﬂammation of the optic nerve, forming lesions reminiscent of
neuromyelitis optica [40]. Together, these data suggest that the
effector T cell cytokine phenotype may dictate the trafﬁcking of the T
cells to speciﬁc regions within the CNS, resulting in differential
recruitment of innate immune cells and distinct functional losses.
5. Effector T cells in MS
Historically, myelin-speciﬁc T cells have been found in both MS
patients and healthy individuals, which raised questions as to the
relevance of these cells in MS patients. However, the observation that
myelin-speciﬁc T cells from MS patients were more likely to have a
TH1 phenotype gave validity to the hypothesis that these cells were
potentially pathogenic in MS patients [47–50]. Subsequently, several
studies demonstrated that although healthy individuals had myelin-
speciﬁc T cells, these cells were naïve; whereas MS patients had
activated and memory myelin-speciﬁc T cells, indicating that these
cells had been previously activated in vivo [51–53]. In addition, a
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(MBP), which was intended to down-regulate myelin-speciﬁc T cells,
actually exacerbated disease in several MS patients which was
associated with increased frequency of MBP-speciﬁc T cells that
produced IFNγ, suggesting that MS is mediated bymyelin-speciﬁc TH1
cells [54].
A decade ago it was found that IL-17 mRNAwas augmented in the
blood and CSF of MS patients, with IL-17 transcript levels higher in
blood than CSF, as well as higher levels in blood during clinical
exacerbations increased [55]. Subsequently, DNA microarray anal-
ysis of MS tissues indicated that IL-17 was present in MS lesions [56].
In 2005, a comprehensive analysis of cytokines expressed in the CSF
of conventional MS and opticospinal MS was performed [57]. The
Th1 cytokines, IFNγ and TNFα, were both higher in MS patients, but
only the TNFα levels were statistically signiﬁcant. However,
comparison of number of CD4 T cells that expressed IFNγ was
signiﬁcantly higher the CSF lymphocytes relative to blood lympho-
cytes of MS patients, regardless of subtype of disease. In addition, the
IFNγ/IL-4 ratio of CD4 T cells was signiﬁcantly increased in
conventional MS patients. IL-17 expression in the CSF of opticospinal
MS patients was also signiﬁcantly increased relative to controls and
conventional MS. The spatial distribution of lymphocytes within the
CNS of mice with EAE induced by IL-23 driven Th17 cells found
extensive lymphocyte inﬁltration in the spinal cord from the subpial
surface to deep within the white matter parenchyma, as well as
extensive inﬂammation of the optic nerve, both characteristics of
opticospinal MS [40].
An extensive comparison of Th1 and Th17 cells in the peripheral
blood and CSF of MS patients found that the absolute number of Th1
cells both in the blood and CSF is about 10-fold higher than the
number of Th17 cells [39], indicating that Th1 effector cells are
signiﬁcantly more prevalent both in the periphery and target organ in
MS patients. However, there was a statistically signiﬁcant increase in
the number Th17 cells in the CSF during an exacerbation in MS
patients that was not observed in the Th1 cells. This may be due to a
role of Th17 cells in the exacerbation, but may also be due to the fact
that the number of Th1 cells is already so much higher that changes
may be more difﬁcult to discern. IL-23 has been found to induce IL-17
expression in human memory CD4 T cells, with a signiﬁcant
proportion of these cells co-expressing IFNγ [58]. Although both
Th1 and Th17 cells have been found capable of crossing the blood–
brain barrier, the IFNγ+IL-17+ T cells in MS patients appear to cross
the blood–brain barrier more efﬁciently, suggesting that this unique
population of effector T cells may have greater encephalitogenic
capacity [58].
Several clinical trials have been performed to determine if
targeting effector T cells may be beneﬁcial for MS patients. As
early as the mid 1980s, the potential contribution of cytokines in
regulating aberrant immune responses was recognized, prompting a
clinical trial using IFNγ to treat MS patients which resulted in an
increased number of exacerbations[59]. It was subsequently found
that IFNγ induces apoptosis in human oligodendrocytes, and in MS
lesions IFNγ expression colocalizes with apoptotic oligodendrocytes
[60,61], indicating that IFNγ contributes to the pathology observed
in MS lesions. These observations led to a clinical trial in which a
neutralizing antibody speciﬁc for IFNγ was administered to MS
patients, demonstrating a therapeutic beneﬁt [62]. This trial was
conducted at the same time as the EAE experiments in IFNγ-
deﬁcient mice and the anti-IFNγ treatment studies in EAE, which
resulted in exacerbated disease [15,16]. The contradictory data
between the human and mouse treatment studies with anti-IFNγ
generated concern that inhibiting IFNγ may have unforeseen
negative consequences. The role of IL-12/IL-23 pathways in
mediating MS was recently tested in a phase II clinical trial in
which MS patients were given a neutralizing antibody to the p40
subunit common to IL-12 and IL-23 [63]. In theory, this antibodyshould prevent the differentiation of Th1 cells mediated by IL-12 and
prevent the production of IL-17 mediated by IL-23. No signiﬁcant
changes in new gadolinium-enhancing lesions or clinical ﬁndings
were observed. The negative outcome of this study does not
necessarily mean that the IL-12/IL-23 is an inappropriate therapeu-
tic target. The MS patient population was quite diverse in disease
severity and duration, and since the IL-12/IL-23 pathway is critical
during T cell differentiation, many of the patients may have esta-
blished effector T cell populations that may mediate pathology
independent of the IL-12/IL-23 pathway. In addition, it is unclear
whether the antibody can and must access the CNS to neutralize T
cells in the target organ.
IFNβ, the most commonly prescribed immunomodulatory therapy
for relapsing-remitting MS, has already been shown to mitigate
effector T cells. IFNβ therapies have been shown to dampen Th1
responses [64], but the ability of IFNβ to attenuate Th17 responses is
controversial. In vitro studies of human CD4 T cells found that IFNβ
inhibited Th17 cell differentiation and could induce apoptosis in Th17
cells [65,66]. However, an ex vivo analysis of IFNγ and IL-17 mRNA, as
well as their respective transcription factors, T-bet and RORC,
demonstrated that IFNβ therapy for one year resulted in decreased
IFNγ and T-bet levels but no signiﬁcant changes in IL-17 or RORC
expression [67]. Interestingly, decreases in T-bet mRNA levels were
only associated with patients who had a clinical beneﬁt from IFNβ
therapy, suggesting that T-bet expression may be a prognostic
indicator of IFNβ responsiveness in MS patients. This supports the
hypothesis that T-bet is critical for T cell encephalitogenicity,
irrespective of T cell cytokine phenotype.6. Conclusion
Although the exact roles of Th1 and Th17 cells in the deve-
lopment of MS lesions are not established, it appears that both of
these effector T cell populations can cause CNS inﬂammation and
demyelinating lesions. The data in mice deﬁcient in various
cytokines, trafﬁcking molecules and transcription factors indicate
that encephalitogenic T cells have multiple critical molecules that
give them the capacity to induce CNS inﬂammation. The observation
that VLA4 high expressing Th1 cells are encephalitogenic, while
VLA4 low expressing Th1 cells are not encephalitogenic illustrates
that all Th1 cells are not equal in their pathogenic capacity [36].
Similarly, the observation that T-bet positive Th17 cells are
encephalitogenic, while T-bet negative Th17 cells are not enceph-
alitogenic demonstrates that Th17 cells differ in their pathogenic
potential because of a transcription factor previously known for its
role in Th1 cells [27]. The data in EAE does demonstrate that there
are pathways mediated by T-bet and Stat 4 that are clearly important
in encephalitogenicity [6,7,10,11,27]. In addition, IL-23, IL-1β and IL-
6 appear to contribute signiﬁcantly to disease onset [20,21,27,68–
70]. Whether these various transcription factors and cytokines
all contribute to a common, yet undeﬁned pathway, or act in a
synergistic manner which culminates in encephalitogenicity has still
to be determined. Analysis of the various molecules, previously
shown to play a vital role in EAE, in MS patients has proven to be
complicated and sometimes contrary to what has been observed in
EAE. In particular, anti-IFNγ therapy was not beneﬁcial in EAE, but
showed promising results in a small clinical trial in MS [62].
However, VLA4 and T-bet expression appear to be involved in
effector T cells in MS patients, similar to what has been shown in
EAE. Therefore, the focus of research on effector T cells in MS should
focus on pathways upstream of the cytokines that deﬁne Th1 and
Th17 cells, since downstream products, such as IFNγ and IL-17,
probably are not critical determinants of whether an effector T cell
is capable of trafﬁcking to the CNS and inducing inﬂammatory
demyelination.
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